Our research program employs functionalized nanomaterials in medicine. We are a part of the Department of Biomedical Engineering. Our expertise is in the development of animal models of cancer, kidney disease and metals-related diseases, and in the development of engineered nanomaterials to diagnose, prevent and treat such diseases.
Aug 11, 2017
Yantasee Lab in collaboration with PDX Pharmaceuticals, LLC was recently awarded a $325,000 Phase I SBIR grant from the National Center for Advancing Translational Sciences, entitled Development of topical formulation of siRNA-nanoparticle for treating skin diseases, R43TR001906, from Aug 2017 to Aug 2018.
May 16, 2017
Yantasee Lab in collaboration with Dr. Joe Gray and PDX Pharmaceuticals, LLC was recently awarded a $1.7M Fast-Track Phase I/II SBIR grant from the National Cancer Institute, entitled Nanoparticle-based targeted co-delivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer, R44CA217534, from May 2017 to May 2020.
About Dr. Yantasee
In addition to her position as Associate Professor at OHSU, Dr. Yantasee is also a Research Member of the Knight Cancer Institute and a Nanomedicine Signature Researcher at Oregon Nanoscience and Microtechnologies Institute (ONAMI).